Improve assessment of individual patient’s responses and toxicity profiles to specific therapies, to radically change the meaning of personalized medicine.
Our cutting-edge genetic research discovered a new class of genetic biomarkers that can dramatically change personalized treatment.
MiraDx partners with universities and pharmaceutical companies to utilize our unique genetic research to help better treat cancer. MiraDx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D. whose cutting-edge genetic research discovered this new class of genetic biomarkers.
Joanne Weidhaas, M.D., Ph.D., M.S.M
Joanne is co-founder of MiraDx and Professor at the David Geffen School of Medicine at UCLA and head of translation research, in the Department of Radiation Oncology. Her pioneering research led to the co-discovery of the KRAS-variant, a strong predictor of cancer risk, tumor biology and treatment response. Her passion to empower individuals with meaningful information to help them take charge of their health led her to found MiraKind and MiraDx. Joanne completed her oncology training at Memorial Sloan-Kettering Cancer Center in New York City and previously served as the Chief of the Breast Cancer Radiation Service at Yale Cancer Center and the Radiation Section Chief of Breast Cancer at the Yale Cancer Center. While on sabbatical at Yale she completed an MBM at Stanford University. She moved to UCLA as Professor and Division Head, Translational Research in 2014. Her dual role as a clinician and researcher has enabled her to apply genetic breakthroughs to the benefit of her patients. She currently lives in the LA area, with her husband and three children.
Frank Slack, Ph.D.
Frank is a co-founder of MiraDx and currently the Shields Warren Mallinckrodt Professor, Department of Pathology, and Director of the Institute for RNA Medicine, at BIDMC.
Andrew J. Weidhaas
Board of Directors
A.J. is a partner in and co-chair of Goodwin Procter’s Private Equity Group, as well as a member of its Technology Companies Practice. He specializes in private equity and
Mary Lake Polan, M.D., Ph.D., MPH
Board of Directors
Dr. Polan is an Adjunct Professor in the Department of Obstetrics and Gynecology and Reproductive Sciences at Columbia University School of Medicine as well as Chair Emeritus of
Roy Vagelos M.D.
Medical Advisory Board
Dr. Vagelos is the Chair of the Columbia University School of Physicians and Surgeons Development Campaign and of the board of directors of Regeneron Pharmaceuticals. He is former CEO, Chairman and Senior Vice President for Research of Merck.
Richard Gatti, MD, Ph.D.
Laboratory Director, Advisor
Dr. Gatti is an emeritas distinguished professor of Pathology and Laboratory Medicine at UCLA. He is a world-renowned molecular geneticist and immunologist and a pioneer in transplantation medicine. Dr. Gatti specializes in Ataxia Telangiectasia,
Advisor, Women’s Health
Sara began her career in the fields of health policy research and healthcare management consulting, with a specific interest in women’s health. After earning her master’s degree in business administration from the Stanford Graduate School of Business,
Clinical Laboratory Scientist
Jean Reiss is currently working at MiraDx Inc. as CLS since MiraDx moved to California in July, 2015 responsible for assay validation, clinical sample testing and required quality controls procedures.
Prior to MiraDx Inc. Jean Reiss retired in 2014 after 22 years of services from Molecular Diagnostics Laboratories